TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
LOS ANGELES, July 12, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) concerning possible violations of federal securities laws between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the September 5, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, throughout the Class Period, Ocular made false and/or misleading statements and/or failed to disclose: that the Company’s management misled investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular contain bad product; that such manufacturing issues could endanger the approval of DEXTENZA by the FDA; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. Upon release of this news, shares of Ocular fell in value materially, which caused investors harm according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
